We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Diabetes

Journal Scan / Research · October 20, 2021

Insulin Degludec and Glargine U100 Treatment in T1D Patients Prone to Nocturnal Severe Hypoglycaemia

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomised, controlled, open-label, cross-over trial
Diabetes Obes Metab 2021 Oct 12;[EPub Ahead of Print], U Pedersen-Bjergaard, RM Agesen, JMB Brøsen, AC Alibegovic, HU Andersen, H Beck-Nielsen, P Gustenhoff, TK Hansen, C Hedetoft, TJ Jensen, CB Juhl, AK Jensen, SS Lerche, K Nørgaard, HH Parving, AL Sørensen, L Tarnow, B Thorsteinsson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading